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Bleeding After HeartMate II
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A Cloud in the Silver Lining*
James O. Mudd, MD, Jill M. Gelow, MD, MPH
Portland, Oregon
Over the past decade, great advances have been made in
mechanical circulatory support as a therapy for end-stage
heart failure. Early device technology improved survival
compared with medical therapy, but long-term durability
was limited (1). Despite these challenges, pulsatile im-
plantable left ventricular assist device (LVAD) technology
was a groundbreaking achievement and laid the foundation
for future devices. Compared with pulsatile devices, the
current generation of ventricular assist device therapy
provides a more stable platform for bridging patients to
transplant and allows long-term destination support for
appropriate candidates with end-stage heart failure (2,3). In
addition to improvements in device technology, center
experience, center volume, and reﬁnements in candidate
selection have resulted in improved outcomes with a 2-year
survival of 70% (4).
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However, widespread use of LVAD therapy and exten-
sion of this technology to lower-risk patients remains limited
by the morbidity of long-term mechanical support. The
most notable of these complications are drive-line infections,
hemorrhagic and embolic stroke, and early and late bleeding.
Bleeding requiring red blood cell transfusions may
contribute to infection, right heart failure, and alloantibody
sensitization. Capturing these data is extremely important
given the associated mortality risks of early blood cell
transfusion after cardiac surgery and HeartMate II (Thoratec
Corp., Pleasanton, California) implantation (5–7). Similarly,
red blood cell transfusions may result in alloantibody
sensitization, which can increase waitlist times and risk of
rejection for patients bridged to cardiac transplantation.
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individual risk remains difﬁcult in the current era.
The initial experience with the pulsatile HeartMate
VE LVAD (Thoratec Corp. in the pivotal REMATCH
(Randomized Evaluation of Mechanical Assistance for the
Treatment of Congestive Heart Failure) trial required only
antiplatelet therapy with aspirin with or without dipyr-
idamole. The frequency of bleeding was 42% at 6 months,
with 0.46 perioperative bleeding events per patient-year and
a non-neurologic bleeding rate of 0.56 events per patient-
year (1). As technology advanced to continuous-ﬂow
devices, so did anticoagulation and antiplatelet require-
ments. The BTT (Bridge-to-Transplantation) trial (2) with
the HeartMate II continuous-ﬂow LVAD required aspirin,
dipyridamole, and warfarin anticoagulation with bridging
heparin. Bleeding was the most common adverse event, with
a transfusion of more than 2 U of packed red cells occurring
at an overall event rate of 2.09 per patient-year and with an
early event rate of 8.33 within the ﬁrst 30 days (2). In the
HeartMate II destination therapy trial, 81% of HeartMate II
and 76% of HeartMate VE patients had bleeding requiring
red blood cell transfusion (p ¼ NS) (3). Given the increased
risks of bleeding and low pump thromboembolism rate in
the HeartMate II clinical trials, many clinicians began to
implement a more conservative anticoagulation strategy,
including eliminating the use of post-operative heparin to
avoid excess bleeding. A retrospective analysis of the
HeartMate II BTT trial demonstrated that no heparin
bridging resulted in less hemorrhagic bleeding without
a difference in pump thrombosis (8). In addition, a shift in
international normalized ratio (INR) goal has occurred since
the initial trials, with a recommended lower target of 1.5
to 2.5 (9,10).
In the current post-trial era deﬁned by modiﬁed anti-
coagulation strategies and evolving center experience, the
longitudinal risks and implications of bleeding events after
HeartMate II implantation are unclear. In this issue of the
Journal, Bunte et al. (11) review their single-center experi-
ence of bleeding in patients supported with the HeartMate
II continuous-ﬂow LVAD. Their analysis focused on the
timing, trends, and types of bleeding after HeartMate II
implantation. The INTERMACS (Interagency Registry for
Mechanically Assisted Circulatory Support) registry is
a robust source of data to understand outcomes in patients
with mechanical support. However, registry deﬁnitions may
not completely capture the clinical course of a patient with
mechanical support, and such is the case with bleeding
deﬁnitions. Bunte et al. (11) broadened their major bleeding
deﬁnition to include anemia of undetermined source (AUS)
that results in any red blood cell transfusion. Using this
transfusion-sensitive deﬁnition, they found AUS was re-
sponsible for 20% of bleeds in the early post-operative period
with a pattern similar to thoracic and gastrointestinal (GI)
bleeding. AUS may represent thoracic bleeding not
requiring reoperation or occult GI bleeding with no endo-
scopic source, which highlights the challenges of evaluating
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extremely important given the risks of red cell transfusion,
and this important paper highlights the potential for
underestimating bleeding risk using current INTERMACS
deﬁnitions alone. In our ﬁeld, we continue to struggle to ﬁnd
the optimal balance of anticoagulation to avoid bleeding and
thrombotic complications (6). Bunte et al. (11) demon-
strated an era effect when early heparin bridging increased
the risk of early bleeding complications, a ﬁnding similar
to other studies (8). The current report expands on our
understanding of the hazard phases of bleeding after
HeartMate II implantation, with most patients (56%) ex-
periencing a single bleed in the early post-operative phase
and showing that an initial bleed does not predict subse-
quent bleeding events. Interestingly, the INTERMACS
proﬁle was not a predictor of bleeding, although early
bleeding events were a predictor for death, with a second
bleeding event resulting in a decreased survival compared to
those with none or ﬁrst bleeding events. An important
observation was the lack of INR as a predictor for initial or
recurrent bleeding events. This may represent the limitations
of INR monitoring as a robust indicator of anticoagulation
status or the heightened vigilance of INR management after
a bleeding or thrombotic event. Additionally, this paper
is a single-center experience with a lower 2-year survival
than seen in the current INTERMACS report, and thus
generalizing the outcomes and ﬁndings requires further
investigation (4).
Future areas of research using the expanded criteria for
bleeding from Bunte et al. (11) include evaluating a pure
destination therapy population. In this study, only 22% of
patients were implanted as destination therapy and the
overall cohort was younger than the HeartMate II destina-
tion therapy trial patients (3). This is important because
older patients are at increased risk for perioperative bleeding
and gastrointestinal arteriovenous malformations that may
increase early and late bleeding events.
As circulatory support technology evolves, so might the
scope and risks associated with bleeding. The third-
generation centrifugal HeartWare HVAD (HeartWare
International, Framingham, Massachusetts) is now approved
for BTT in the United States based on the initial trial, in
which 14.8% of patients had bleeding requiring reoperation
and 12.7% had GI bleeding, with most of the latter events
occurring after the ﬁrst 30 days (13). Interestingly, 86% of
patients were free from GI bleeding at 1 year with a GI
bleeding rate of 0.26 events per patient-year, which is
a lower event rate than seen in the HeartMate II BTT trial
(13). However, many factors may account for these differ-
ences, including device design, anticoagulation strategies,
patient characteristics, trial design, and bleeding deﬁnitions.
What these rates would be with the transfusion-sensitive
bleeding deﬁnition proposed by Bunte et al. (11) is unclear.
The balance between bleeding and thrombosis is not ex-
amined in the present study but is an important considerationin establishing anticoagulation protocols and tailoring them
to patients. Identifying risk factors for thrombosis is an
evolving ﬁeld, and balancing bleeding and thrombotic risks
remains a challenge. Given the morbidity and mortality of
bleeding after LVAD implantation, the standard registry
deﬁnitions of bleeding events should be modiﬁed to a more
transfusion-sensitive deﬁnition, as demonstrated in the
current report. Further efforts to accurately capture the
subtypes and phases of bleeding and the impact of trans-
fusions in this population are critical to improving morbidity
and long-term outcomes in patients supported with
continuous-ﬂow devices.
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